Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. [PDF]
, 2019 Despite tremendous efforts to fight cancer, it remains a major public health problem and a leading cause of death worldwide. With increased knowledge of cancer pathways and improved technological platforms, precision therapeutics that specifically target
Bivona, Trever G +8 more
core +1 more source
Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment [PDF]
, 2017 The tumor microenvironment plays a key role in tumor development and progression. Stromal cells secrete growth factors, cytokines and extracellular matrix proteins which promote growth, survival and metastatic spread of cancer cells.
Galemmo, Robert +3 more
core +2 more sources
Autophagy and urothelial carcinoma of the bladder: A review. [PDF]
, 2016 The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the
Chandrasekar, Thenappan +1 more
core +2 more sources
Cancer microcell initiation and determination
BMC Cancer, 2021 Background Cancer remains one of the leading causes of death worldwide, despite the possibilities to detect early onset of the most common cancer types.
Zane Simsone +7 more
doaj +1 more source
Resisting Resistance: Targeted Therapies in Lung Cancer [PDF]
Trends in Cancer, 2016 Drug resistance inevitably limits the efficacy of all targeted therapies including tyrosine kinase inhibitors (TKIs). Understanding the biological underpinnings of TKI resistance is key to the successful development of future therapeutic strategies. Traditionally, mechanisms of TKI resistance have been viewed under a dichotomous lens.
Jessica J, Lin, Alice T, Shaw
openaire +2 more sources
hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. [PDF]
, 2015 Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 ...
Circo, R +11 more
core +2 more sources
Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST)
Bio-Protocol, 2020 The binding interactions of PD-1 and PD-L1 have been studied by surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) over the past few years, but these investigations resulted in controversy regarding the values of the dissociation ...
Magnez Romain +4 more
doaj +1 more source
eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]
, 2019 CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina +13 more
core +1 more source
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Cells, 2021 Molecular alterations in cancer genes and associated signaling pathways are used to inform new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal antibodies directed at relevant cancer-related proteins have been ...
Hon Yan Kelvin Yip, Antonella Papa
doaj +1 more source
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. [PDF]
, 2018 The goal of anticancer therapy is to selectively eradicate all malignant cells. Unfortunately for the majority of patients with metastatic disease, this goal is consistently thwarted by the nearly inevitable development of therapeutic resistance; the ...
Cabrales, Pedro +5 more
core +2 more sources